{"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.79","pValueComment":"Two-sided significance level = 0.05","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.5","upperLimit":"12.7","value":"9.2"},{"groupId":"OG001","lowerLimit":"5.8","upperLimit":"11.8","value":"8.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"368"},{"groupId":"OG001","value":"356"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin\n\nCisplatin: 100 mg/m2 IV on days 1 and 22 of IMRT\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG000","title":"IMRT + Cisplatin"},{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab\n\nCetuximab: 400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG001","title":"IMRT + Cetuximab"}],"paramType":"NUMBER","populationDescription":"Eligible patients who started study treatment and had feeding tube assessment at 1 year","reportingStatus":"POSTED","timeFrame":"From randomization to 1 year.","title":"Percentage of Participants With a Feeding Tube at 1 Year","type":"SECONDARY","unitOfMeasure":"percentage of participants"}